secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001437749-25-011986
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Therapeutics FY2024 net loss $1.8M; cash $1.8M; pivots to revenue-generating acquisitions
--------------------------------------------------------------------------------

- Net loss $1.8M vs $20.3M in 2023; loss per basic share $104.35 on $5.5M net loss attributable to common.
- Cash and equivalents $1.8M at Dec 31, 2024; raised ~$2.3M post-period, funding operations only through April 2025.
- New corporate strategy: use equity to acquire small biotech firms with FDA-approved products; signed Evofem deal for PHEXXI distribution.
- Positive Phase 2 SEISMiC Extension for istaroxime in early cardiogenic shock; SEISMiC C trial enrolling, interim data in Q3 2025.
- R&D spend rose to $16.3M from $8.3M, driven by $7.5M Varian IPR&D charge and increased istaroxime development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774925011986/0001437749-25-011986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774925011986/wint20241218_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-011986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer